ClinicalTrials.gg
RecruitingNCT04261244NeoRadUpdated May 7, 2025

NeoRad Breast Cancer Study

A Phase 3 interventional study of preoperative radiotherapy and postoperative radiotherapy in Breast Cancer, sponsored by Bielefeld University. Recruiting at 16 sites in Germany. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-07.

Sponsored by Bielefeld University · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,826
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 678 studies in Breast Neoplasms with a site in Germany — 114 open to participants now, 196 under way, 81 of them phase 3. Breast Neoplasms · Germany.

Planned enrollment
56th of 580
1,826 · median 273
Started
2024
with 27 others
Phase 3
222 of 678
29 open now
Primary completion
2028-03
later than 117 of 195 live
Registered
462nd of 678
by date

Among the 678 studies in Breast Neoplasms with a site in Germany, this one is the 56th largest by planned enrollment of the 580 interventional ones that give a count, is one of 28 that started in 2024, is one of 222 in phase 3, reaches primary completion later than 117 of the 195 other live ones, and was the 462nd registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

114 of the 678 studies in Breast Neoplasms with a site in Germany are open now. Recruiting first, the newest first:

109 more — sign in →

All 114 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 678 studies in Breast Neoplasms with a site in Germany, or all of them as a file.
02

Study summary

The NEORAD trial tests whether preoperative radiotherapy results in an improved DFS and less radiation induced late effect compared to postoperative radiotherapy in higher risk breast cancer after NACT.

Read the detailed description

The standard of care for high-risk breast cancer consists of neoadjuvant chemotherapy and surgery followed by postoperative whole breast/chest wall irradiation+/- an additional boost (= irradiation restricted to the tumour bed in the case of breast-conserving therapy). In case of lymph node involvement in most patients require additional radiation of the regional lymph nodes. Adjuvant radiotherapy significantly reduces ipsilateral breast cancer recurrences, breast cancer specific mortality, and overall mortality. The optimal time of radiotherapy in patients, who are candidates for neoadjuvant chemotherapy (NACT) has never been addressed in a randomised controlled trial.

The Study Chairman of the NEORAD trial is Prof. Dr. med. Christiane Matuschek. The deputies of the Study Chairman are Prof. Dr. med. Wilfried Budach and Prof. Dr. med. Tanja Fehm.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • neoadjuvant chemotherapy
  • preoperative radiotherapy
  • capsular contraction
  • immediate reconstruction
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • proven invasive, unilateral breast cancer
  • Indication for radiotherapy
  • Indication for chemotherapy (+/- antibody treatment or other targeted therapies) in accordance with national and international guidelines
  • Female
  • for the trial signed by the patient
  • Hormone receptor and status: no restrictions
  • All grades G1-G3
  • Age ≥ 18 years at the time of informed consent
  • Performance status ≤ 2
  • No pre-existing conditions that prohibit therapy

Exclusion criteria

Exclusion Criteria:

  • treatment solely with endocrine therapy
  • Bilateral breast cancer
  • Pregnancy or lactation
  • Prior radiotherapy of the thorax
  • Connective tissue disease, including rheumatoid arthritis and thromboangiitis obliterans
  • Pre-existing symptomatic chronic lung disease (fibrosis, pneumoconiosis, adult-onset allergies, such as farmer's lung, severe lung emphysema, °III)
  • Cardiac comorbidities: symptomatic coronary heart disease, prior heart attack, heart failure ≥II or AHA ≥C, pacemaker, and/or implanted defibrillator
  • Malignoma except basalioma or in-situ-carcinomas in complete response
  • Distant
  • Plexopathies of the arm of the treated side
  • Stiffness of the shoulder of the arm of the side of the breast cancer of any origin (e.g. following a road accident)
  • Lymph edema ≥°II of the arm at the side of the breast cancer
  • Other medical conditions that prohibit the neoadjuvant radiotherapy (i.e. Expected non-compliance, etc.)
  • Male patients
  • Patients who have previously been assessed for chemotherapy response
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,826 participants (estimated)

Study arms

  • Experimental
    Experimental Arm

    preoperative radiotherapy in breast cancer after neoadjuvant chemotherapy

    Radiation: preoperative radiotherapy

  • Active comparator
    Standard treatment

    standard treatment (postoperative radiotherapy) in breast cancer after neoadjuvant chemotherapy

    Radiation: postoperative radiotherapy

Interventions

  • Radiationpreoperative radiotherapy

    preoperative radiotherapy instead of postoperative radiotherapy in breast cancer after neoadjuvant chemotherapy

  • Radiationpostoperative radiotherapy

    postoperative radiotherapy in breast cancer after neoadjuvant chemotherapy

06

What researchers measure

Primary outcomes

  1. disease free survival (DFS):

    Time interval in which the patient does not show any signs or symptoms of the treated cancer (local or regional recurrence, distant metastases, or death of any cause) beginning after randomisation to a study arm. This is a way to measure how well the new treatment is working.

    Time frame: 6 to 10 years

Secondary outcomes

  1. local recurrence rate [in affected breast] (LR)

    Rate of cancer that has recurred at the same location as the primary cancer. This is a way to measure how well the new treatment is working.

    Time frame: 6 to 10 years

  2. locoregional recurrence rate (LRR)

    Rate of new cancer at any locations (regional lymph nodes, chest wall/mastectomy site) on side which was previously affected by the primary cancer. This is a way to measure how well the new treatment is working.

    Time frame: 6 to 10 years

  3. disease metastases free survival (DMFS)

    Time interval beginning after randomisation in which the patient survives and the cancer has not metastasized. This is a way to measure how well the new treatment is working.

    Time frame: 6 to 10 years

  4. overall survival (OS)

    Length of time beginning after randomisation in the study that the patient survives. This is a way to measure how well the new treatment is working.

    Time frame: 6 to 10 years

  5. disease specific survival (DSS)

    Length of time from the beginning of the study after randomisation in a study arm that the patient survives the specific cancer. This is a way to measure how well the new treatment is working.

    Time frame: 6 to 10 years

  6. Assesment of cosmetic results by the physicians and the patient using a 5 point Scoring System*

    A grading scale is provided for cosmetic results (5 Point Scoring System): E0 Excellent aesthetic result: At first sight no visible therapy sequellae. Both breasts have a similar appearance E1 Good: minimal changes in pigmentation, a visible scar, localized teleangieectasia. E2 Moderate: marked sequellae with a clear deformation of the breast contour, nipple displacement, or marked skin changes, but yet "acceptable". E3 Bad: severe retraction or fibrosis, severe teleangiectasia. E4 Complications: skin necrosis

    Time frame: 6 to 10 years

  7. Assesment of cosmetic results by the physicians using breast retraction assessment-Score (BRA Score)*

    \*The BRA Score measures breast symmetry of the treated breast in comparison to the untreated breast. The average in the general population is 1.2 cm. A higher BRA score is worse. A BRA score of 0 cm is optimal.

    Time frame: 6 to 10 years

  8. Measurement of the quality of life (QOL): functional scale

    QoL will be assessed by EORTC (European Organisation for Research and Treatment of Cancer) QLQ-C30 questionnaires for overall QoL and EORTC QLQ-BR23 for breast-specific QoL. The QLQ-C30 consists of 30 questions categorized in functional and symptom-specific scales and provides a global score through two general questions concerning health and quality of life. QLQ-BR23 is a standard instrument for measuring QoL in patients with breast cancer. The questionnaire has 23 items with four possible answers each (not at all, a little, quite a bit, very much). Results are reported using functional scales (e.g. body image, sexual functioning) and symptom-related items (e.g. systemic therapy side effects, breast symptoms). It is also common practice to classify the summary scores into four distinct categories with functional scales (0-25 bad; 26-50 moderate; 51-75 good; 76-100 excellent) and symptom-related scales.

    Time frame: 6 to 10 years

  9. Measurement of the quality of life (QOL): symptom-related scale

    QoL will be assessed by EORTC (European Organisation for Research and Treatment of Cancer) QLQ-C30 questionnaires for overall QoL and EORTC QLQ-BR23 for breast-specific QoL. The QLQ-C30 consists of 30 questions categorized in functional and symptom-specific scales and provides a global score through two general questions concerning health and quality of life. QLQ-BR23 is a standard instrument for measuring QoL in patients with breast cancer. The questionnaire has 23 items with four possible answers each (not at all, a little, quite a bit, very much). Results are reported using functional scales (e.g. body image, sexual functioning) and symptom-related items (e.g. systemic therapy side effects, breast symptoms). It is also common practice to classify the summary scores into four distinct categories with functional scales and symptom-related scales: (0-25 excellent; 26-50 good; 51-75 moderate, 76-100 bad)

    Time frame: 6 to 10 years

  10. Assessment of arm lymphedema rates by the physicians using common toxicity criteria for adverse events CTCAE, version 5.0

    Lymphedema: 'A disorder characterized by excessive fluid collection in tissues that causes swelling.' A grading scale is provided for arm lymphoedema rates higher than Grade 1 of the irradiated side (0= "not present", 1= "Trace thickening or faint discoloration", 2= "Marked discoloration; leathery skin texture; papillary formation; limiting instrumental ADL\*", 3= "Severe symptoms; limiting self care ADL") using common toxicity criteria for adverse events CTCAE, version 5.0 \*ADL = activities of daily living

    Time frame: 6 to 10 years

  11. Assessment of plexopathia higher than Grade 1 of brachial plexus on irradiated side by the physicians using common toxicity criteria for adverse events CTCAE, version 5.0

    Brachial plexopathia:'"A disorder characterized by regional paresthesia of the brachial plexus, marked discomfort and muscle weakness, and limited movement in the arm or hand.' A grading scale is provided for plexopathia of brachial plexus on the irradiated side higher than Grade 1 (0= "not present", 1= "Aysmptomatic; clinical or diagnostic observations only; intervention not indicated", 2= "Moderate symptoms; limiting instrumental ADL\*", 3= "Severe symptoms, limiting self care ADL") using common toxicity criteria for adverse events CTCAE, version 5.0 \*ADL = activities of daily living

    Time frame: 6 to 10 years

  12. Assessment of treatment-related toxicity measured by the physicians using standardized common toxicity criteria for adverse events CTCAE, version 5.0.

    A grading scale is provided for each side effect (0= not present, 1=asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated, 3=moderate; minimal, local or noninvasive intervention indicated; -4=severe or medically significant but not immediately life-threatening)

    Time frame: 6 to 10 years

07

Study locations

16 of 16 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Mar 2028, 49 months after the start.

Of 328 non-industry phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 79 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 127. This study's planned 49 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2019
First posted
Feb 7, 2020
StartActual
Feb 1, 2024
Primary completionEst.
Mar 31, 2028
CompletionEst.
Mar 31, 2034
Last update
May 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04261244
Lead sponsor
Bielefeld University
Responsible party
Sponsor
First posted
Feb 7, 2020
Start date
Feb 1, 2024
Primary completion
Mar 31, 2028 (estimated)
Completion
Mar 31, 2034 (estimated)
Last update
May 7, 2025

Study contacts

Christiane Matuschek, MD Prof.
Contact
christiane.matuschek@uni-bielefeld.de
+495215812901
Deborah Wöstenfeld, M. A.
Contact
deborah.woestenfeld@uni-bielefeld.de
+495215812972
Christiane M Prof., MD Prof.
study chair · Bielefeld University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion